A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of I.M. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Naïve Subjects.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Hepatitis C DNA vaccine (Primary) ; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 02 Apr 2013 Interim results published in the Media Release.
- 02 Apr 2013 Primary endpoint 'Viral-load' has not been met, according to a ChronTech Pharma media release.
- 25 Jan 2013 Results will be reported in the first quarter of 2013 according to a ChronTech Pharma media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History